<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Reau, Nancy S.</style></author><author><style face="normal" font="default" size="100%">Naggie, Susanna</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">New Treatment Paradigm for HCV and HCV/HIV Coinfection</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-08-07 10:43:03</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">25-27</style></pages><abstract><style  face="normal" font="default" size="100%">New treatment regimens utilizing combinations of protease (nonstructural protein 3-4A [NS3-4A]), nucleotide (NS5B), nonnucleoside (NS5B), and NS5A inhibitors are successfully being used to treat patients with hepatitis C virus coinfected with HIV. Sustained virologic response rates of ≥ 90% are achieved after 12 to 24 weeks in patients with and without cirrhosis who are treatment naïve and experienced. HIV is no longer a predictor of poorer response to hepatitis C virus therapy.</style></abstract><number><style face="normal" font="default" size="100%">14</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>